Related Experiment Video

Updated: Jun 16, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear

Junxia Min1, Alexander Zaslavsky, Giuseppe Fedele

  • 1Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Nature Medicine
|February 16, 2010
PubMed

Insights

Loss of DAB2IP, a tumor suppressor, drives prostate cancer growth and metastasis by activating Ras and NF-kappaB. EZH2 epigenetically silences DAB2IP, promoting cancer spread and poor prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer metastasis is a leading cause of cancer-related death.
  • The molecular mechanisms driving prostate cancer metastasis remain incompletely understood.
  • Identifying key molecular regulators is crucial for developing targeted therapies.

Purpose of the Study:

  • To elucidate the oncogene-tumor suppressor cascade regulating prostate cancer growth and metastasis.
  • To investigate the role of DAB2IP in prostate cancer progression.
  • To determine the mechanism by which EZH2 contributes to prostate cancer metastasis.

Main Methods:

  • Utilized an orthotopic mouse tumor model to study metastatic prostate cancer.
  • Investigated the signaling functions of DAB2IP in regulating Ras and NF-kappaB pathways.
  • Analyzed DAB2IP expression in human prostate cancer tissues and correlated it with tumor grade and prognosis.
  • Examined the role of EZH2 in the epigenetic silencing of DAB2IP.

Main Results:

  • Loss of DAB2IP (a Ras GTPase-activating protein) induced metastatic prostate cancer in mice.
  • DAB2IP acts as a signaling scaffold, coordinating Ras and NF-kappaB activation for tumor growth and metastasis.
  • DAB2IP expression is suppressed in human prostate cancer, inversely correlating with tumor grade and predicting poor prognosis.
  • Epigenetic silencing of DAB2IP by EZH2 was identified as a mechanism driving Ras and NF-kappaB activation and metastasis.

Conclusions:

  • A novel oncogene-tumor suppressor cascade involving DAB2IP regulates prostate cancer metastasis.
  • Simultaneous activation of Ras and NF-kappaB pathways is mediated by DAB2IP loss.
  • EZH2 is a key driver of prostate cancer metastasis through epigenetic silencing of DAB2IP.

More Related Videos

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...